Introduction. Women with a history of placenta-related pregnancy complications, such as preeclampsia, intrauterine growth restriction or preterm delivery, have an increased risk for recurrence of such complications. This recurrence is likely the result of underlying endothelial dysfunction that leads to abnormal placentation, especially in complications with an early onset. This study provides an overview of biomarkers of placental development and function in pregnancies from women with a history of placenta-related complications. Material and methods. A systematic literature search was conducted limited to human studies and including keywords related to a history of placenta-related complications and markers of placental development and function. Two independent reviewers assessed eligibility and quality of 1553 retrieved unique articles. Results. Five articles reporting on placental development and function in women with an obstetric history of preeclampsia (n = 3), intrauterine growth restriction (n = 1) and preterm delivery (n = 2) were eligible for quality assessment. We identified associations between a history of preeclampsia and abnormal placental histological findings at term in the current pregnancy, but found contradictory results regarding presence of uterine artery notching. In women with a history of very preterm delivery (<32 weeks), one study showed associations with abnormal placental histology. Conclusion. Literature on the association between a history of placenta-related complications and placental development and function in subsequent pregnancies is scarce and studies are heterogeneous. However, literature shows that placenta-related pregnancy complications are associated with subsequent placental histology.
Introduction
Every year, over 7 million women worldwide develop pregnancy complications that are, at least in part, due to abnormal placental development and functioning and can therefore be referred to as placenta-related complications. These pregnancy complications, such as recurrent miscarriage, pregnancy-induced hypertension, preeclampsia
Key Message
Placentation after placenta-related complications is largely understudied, but available evidence suggests that placental histology is altered after placentarelated complications in previous pregnancies. Future research should assess in vivo placentation in women with a history of placenta-related complications to study these associations.
(PE), intrauterine growth restriction (IUGR) and preterm delivery, are associated not only with abnormal placental development and function, but also with cardiovascular disease in mothers and their offspring in later life (1) (2) (3) (4) .
In the first weeks of pregnancy, placental development is crucial, with the physiological vascular transformation of the spiral arteries into low-resistance vessels as a result of upregulation of maternal inflammatory responses and circulatory changes (5, 6) . This process demands intense effort of a woman's vascular capacity and as such pregnancy is considered a stress test for cardiovascular health (7) . Women failing this stress test are not only at risk to develop placenta-related complications in their current pregnancy, but their risk for recurrence of such complications in future pregnancies is also increased due to underlying cardiovascular risk factors that predispose to endothelial dysfunction (8) . This cardiovascular predisposition may explain the high recurrence risk of placentarelated pregnancy complications, especially in women with an early-onset of such complications. Similarly, in late-onset placenta-related complications, predisposing cardiovascular and metabolic disorders may also induce a cascade of placental and systemic inflammation and oxidative stress, although placental histological examination at term often shows normal villous morphology (2) .
Unfortunately, assessment of placental function during pregnancy remains difficult and tools to assess actual in vivo placental development and function are not yet available. However, in recent years, several biomarkers that reflect placental development and function have been described that can be measured already early in pregnancy (9) (10) (11) (12) . In general, such biomarkers are products derived from processes involved in trophoblast invasion or placental neovascularization (for example serum biomarkers) or maternal and uteroplacental vascular characteristics (for example ultrasound measurements). Furthermore, following miscarriage or delivery, placental histological features can provide information on placental tissue composition and its functionality (13) .
Knowledge on the role of placenta-related pregnancy complications on placental development and function in subsequent pregnancies remains rather limited. The basis for adequate placentation lies in the periconception period, making this a window of opportunity for the identification of women at risk for (recurrence of) placenta-related pregnancy complications and thus provides possibilities for the prevention of such complications. To gain more insight into the pathophysiology of recurrence of placenta-related pregnancy complications we performed a systematic review of the literature on eligible biomarkers for placental development and function in subsequent pregnancies of women with a history of placenta-related pregnancy complications. Ultimately, insights in recurrence may direct future strategies towards risk-counseling, early identification and prevention of the recurrence of placenta-related pregnancy complications in these women.
Material and methods

Search strategy
We conducted a search in Medline, Embase, Pubmed, The Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Methodology Register), Web of Science and Google Scholar. Our search strategy included keywords related to a history of five placenta-related complications as exposure(s), recurrent miscarriage, pregnancy-induced hypertension, PE, IUGR and preterm delivery, which were combined using the Boolean operator "or" (Appendix S1). Studies eligible for inclusion had to focus on placental development and function in subsequent pregnancies, reflected in placental biomarkers, ultrasound parameters or histological characteristics. Reference lists were searched to include any articles that had been missed in the initial search. A protocol of this systematic review has been registered in PROSPERO International prospective register of systematic reviews (2016:CRD42016045637, available from: http://www.crd.york.ac.uk/PROSPERO/dis play_record.asp?ID=CRD42016045637).
Inclusion and exclusion criteria
Articles published between January 2000 and January 2017 and written in English were eligible for inclusion. Eligible studies had to include multigravida or multiparous women with a singleton pregnancy at any gestation with a history of any of the five placenta-related complications as well as a control group of women without a history of such placenta-related complications. We only included randomized trials or observational studies (including cohort and case-control studies). Letters to the editor, conference abstracts, editorials and case reports were excluded. Systematic reviews were excluded after checking relevant references.
Based on the literature, the following groups of markers of placental development and function were included: placental blood biomarkers, placental ultrasound parameters and placental histological characteristics. A standardized data extraction form was used to collect key information from the included studies for assessment of quality and evidence synthesis. Extracted information included study design, study population, methodology (including inclusion period, exclusion criteria, statistical methods and adjustment for confounders), the studied history of placenta-related complications, the moment of onset of these placenta-related complications, the chosen outcome for placental development or function and the study results. Missing data was requested from study authors.
Odds ratios (OR) with corresponding 95% confidence intervals (CI) were calculated for outcomes of placental development and function when outcome prevalence was available in the original article: women with an obstetric history of placenta-related complications and the placental outcome of interest in their current pregnancy (1) were divided by the number of women without an obstetric history of placenta-related complications but with the placental outcome of interest (2) . Next, this number was divided by the number of women with an obstetric history of placenta-related complications but without the placental outcome of interest in their current pregnancy (3), divided by the number of women without an obstetric history of placenta-related complications and without the placental outcome of interest in their current pregnancy (4; OR = (1/2)/ (3/4). For only one outcome (uterine artery notching in women with a history of PE), we were able to calculate a pooled OR, by combining the prevalence of these two studies. Missing data was requested from study authors.
I.R. and M.K. independently conducted a quality assessment of included studies using the predefined ErasmusAGE quality score (Appendix S2), which has been developed by the Rotterdam Intergenerational Ageing Research Center (www.erasmusage.com) from the Erasmus MC and is based on previously published scoring systems (14, 15) . The score is composed of five items for appraisal of randomized trials and observational studies. These items cover study design, study size, description of methods to assess placenta-related complications, outcome of placental development and/or function and correction for confounders in data analysis. For this systematic review, specific quantitative limits for the items (for example what was considered as appropriate study size) were chosen based on literature and discussion among the research group. Each item was allocated zero, one or two points, resulting in a total score between zero and 10, with 10 representing the highest quality.
Results
Study selection
A flowchart of the selection process of articles included for systematic review is shown in Figure 1 . Our literature search yielded 2380 results, leaving 1553 unique articles after exclusion of duplicates. Screening of titles and abstracts led to further exclusion of 1532 articles that not fulfilled the predefined eligibility criteria. The full texts of the remaining 21 articles were screened, resulting in four studies that were eligible for quality assessment. One study was retrieved from relevant reference checking from included articles and systematic reviews. Thus, in total, five studies were included in this systematic review.
Study characteristics and quality assessment
An overview of the baseline characteristics and quality score of the included studies is shown in Table 1 . The quality score of the included articles ranged between two and seven, which can be considered poor to moderate quality. Figure 2 provides a schematic overview of the results of this systematic review. In the next subsections the associations between a history of PE, IUGR or preterm delivery and markers of placental development and function (blood biomarkers, ultrasound parameters and histological features) in a subsequent pregnancy are summarized. None of the articles eligible for inclusion studied the effect of recurrent miscarriage or pregnancy-induced hypertension on placental development and/or function in a subsequent pregnancy. Calculated ORs for outcomes of placental development and function are displayed in Table 2 .
Preeclampsia and intrauterine growth restriction. Three articles described the effect of a history of PE and/or IUGR on placental development and function in a subsequent pregnancy. In none of these articles was a distinction made between early-onset and late-onset PE or IUGR.
A prospective nested case-control study by Tarim et al. (2006) studied the effects of aspirin on perinatal outcomes and placental histology postpartum (16) . In total, 86 women were included and divided into three groups: women without a history of placenta-related complications (n = 30) and women with a history of PE or IUGR treated with (n = 27) and without (n = 29) low-dose aspirin. Results below are only described for women who were not treated with aspirin, as this could have affected outcomes of placental development and function. Histological examination focused on uteroplacental vascular pathologic features and/or secondary villous damage and lesions involving coagulation. Mean placental weight was not significantly different in women with an obstetric history of PE/IUGR (629.3 AE 134.1 g) vs. women without such an obstetric history (632.1 AE 105.1 g). Although not statistically significant, histological abnormalities were approximately two to four times more frequently present in both groups of women with a history of placentarelated complications compared with women without such a history: fibrinoid necrosis of decidual vessels (13.8 vs. 3.3%), villous infarcts (13.8 vs. 3.3%), severely increased villous fibrosis (6.9 vs. 3.3%), severely increased syncytiotrophoblast knotting (13.8 vs. 3.3%), obliteration of the vessel lumen (6.9 vs. 3.3%), severely increased villous hypervascularity (79.3 vs. 76.7%), excessive perivillous fibrin deposition (13.8 vs. 3.3%), multiple occlusive thrombi in uteroplacental vessels (6.9 vs. 3.3%) and avascular villi (6.9 vs. 3.3%).
Another study by Block-Abraham et al. (2014) investigated first-trimester (between 9 and 14 weeks' gestational age) maternal characteristics, Doppler ultrasound parameters and serum biomarkers in a prospective observational cohort study of 1283 parous women (17) . Fifty-two women (4.1%) had PE in a previous pregnancy. In the current pregnancy, no statistically significant differences were found between women with and without a history of PE regarding Doppler pulsatility index z-scores of the uterine arteries [0. 
Not eligible n = 1532
Duplicates n = 1103 Figure 1 . Flowchart of study selection. IUGR, intra-uterine growth restriction; PE, preeclampsia; PIH, pregnancy-induced hypertension.
ª 2017 Nordic Federation of Societies of Obstetrics and Gynecology, Acta Obstetricia et Gynecologica Scandinavica 97 (2018) 248-257 Table 1 . Study characteristics and quality score of included studies. QS total: total quality score, ranging from 0 to 10, resulting from the sum of five sub-items (study design, study size, description of methods and outcomes, adjustment for confounders) (14, 15 Preterm delivery. Two articles focused on women with a history of preterm delivery. A prospective cohort study by Ghidini et al. (2005) studied histological placental lesions after delivery in multiparous women with recurrent very early preterm delivery (<32 weeks of gestational age) (19) . Multiparous women without a preterm delivery (n = 328) with one prior preterm delivery (n = 49) or with two or more prior preterm deliveries (n = 36) were compared. The exact gestational age of these previous deliveries was not reported. No significant differences were present among the three study groups for mean placental weight, the feto-placental weight ratio and the histopathological lesion categories acute inflammation, chronic inflammation, uteroplacental vascular pathology and intraplacental vascular pathology, but regression analysis for individual lesions showed a positive correlation of prior preterm delivery with chronic marginating choriodeciduitis (r = 0.13, p = 0.01) and acute choriodeciduitis (r = 0.14, p = 0.008). Since the prevalence of the placental histological features was not reported, calculation of ORs was not possible for these outcomes.
PE n = 3
Biomarkers (n = 1)
•PAPP-A and b-HCG levels not different (17) Ultrasound (n = 2)
•No difference in first trimester uterine artery Doppler (17, 18) •More uterine artery notching (18) Histology (n = 1)
• Uteroplacental vascular pathologic lesions and secondary villous damage lesions higher, however not significant (16) IUGR n = 1
Ultrasound (n = 0)
• Uteroplacental vascular pathologic lesions and secondary villous damage lesions higher, however not significant (16) Preterm delivery n = 2
Biomarkers (n = 0)
Ultrasound (n = 0) The study of Goldenberg et al. (2006) described postpartum placental histology in 457 women with a spontaneous or indicated very early preterm delivery between 23 and 32 weeks' gestational age in their current pregnancy in a cross-sectional setting (20) . The population was sorted into four groups: nulliparous (n = 234), parous without a history of preterm delivery (n = 111), parous with a history of indicated preterm delivery ≥20 and <37 weeks (n = 83) and parous with a history of spontaneous preterm delivery ≥20 and <37 weeks (n = 29). Percentages of placental findings (divided into the subgroups acute inflammation of the membranes, chorionic plate or umbilical cord and chronic inflammation of the membranes or decidua and diffuse decidual leukocytoclastic necrosis) were not significantly different between these groups. However, when women with obstetric history of indicated and spontaneous preterm birth were grouped together (n = 112), they had a significant higher risk of chronic inflammation in the decidua basalis (OR 2.63, 95% CI 1.10-6.20).
Discussion
In this systematic review, we present an overview of the published literature on associations between women with a history of placenta-related complications and abnormal placental development and function in subsequent pregnancies, implicating underlying endothelial dysfunction and impaired cardiovascular function. Regarding a history of PE, we identified associations with abnormal placental histological findings at term in subsequent pregnancies, such as uteroplacental inflammatory signs or vascular pathologic features. No statistically significant differences were observed for serum levels of pregnancyassociated plasma protein A and free beta human chorionic gonadoptropin or Doppler waveforms of the uterine arteries between women with and without a history of PE. Findings were contradictory regarding the presence of uterine artery notching (17, 18) . In women with a history of IUGR, abnormal placental histological findings were also reported, although these findings were not statistically significant (18) . Varying results were reported for a history of preterm delivery; in one study preterm delivery was associated with acute and chronic marginating choriodeciduitis (19) , while another study reported that a history of preterm delivery did not seem to influence placental histology (20) . In none of the retrieved articles was the effect of recurrent miscarriage or pregnancyinduced hypertension on subsequent placental development and function studied.
Despite the extensive systematic literature search that was performed, only a few eligible studies with relatively limited quality were retrieved. Due to this, as well as the large heterogeneity in outcomes of placental development and function, a meta-analysis could not be performed. We were only able to calculate a pooled OR for uterine artery notching in women with a history of PE, since this was the only parameter that was measured in multiple studies. The retrieved studies were heterogenic in both design and study outcome, making general assumptions and conclusions difficult. We retrieved mainly observational cohort or case-control studies and many studies did not adjust their analysis, making residual confounding a possible factor that may have influenced the studied associations. Some studies used self-reported questionnaires to establish obstetric history, which has less validity than medical records. Moreover, most studies had limited sample sizes and did not perform sample size calculations.
For this review, we have chosen to include the placenta-related pregnancy complications recurrent miscarriage, pregnancy-induced hypertension, PE, IUGR and preterm delivery. Other complications with a possible placental origin are placental abruption and intrauterine fetal death. The etiology of placental abruption is unknown in most cases. However, placental abruption is associated with maternal trauma or maternal disease such as metabolic disorders and inherited thrombophilia as well as lifestyle factors. Consequently, defective placentation rather than maternal vascular inadequacy alone does seem to play a role (21, 22) . Khong et al. also describe that in many cases of placental abruption, no histopathological placental abnormalities are found other than a retroplacental hematoma (21) . We have therefore chosen not to include placental abruption in this systematic review. Furthermore, although we acknowledge that inadequate placentation might lead to intrauterine fetal death as a result of abnormal placentation, the main reason to exclude intrauterine fetal death was due to the largely etiologic heterogeneity of this complication.
In general, the risk for placenta-related pregnancy complications diminishes in parous women. Explanatory pathways often address the effect of the first pregnancy on changes in structural composition of the spiral arteries, i.e. persistence of a more compliant and distended spiral arterial wall resulting from trophoblast invasion. This leads to more effective remodeling of spiral arteries in future pregnancies. A study by Khong et al. (23) showed that the structural changes induced by pregnancy were not completely obliterated after birth. Moreover, Prefumo et al. (24) described more extensive trophoblastic invasion of the decidual vessels in parous compared with nulliparous women. An animal study into nitric oxide deficiency in the first pregnancy, which may hamper the physiologic vascular adaptation in pregnancy, observed a more physiological vascular adaptation in the second pregnancy (25) . Recently, Ballering et al. (26) stated that multiparous women have a different initial course of early placental vascular development from nulliparous women when expressed in ultrasound placental vascularization indices and blood biomarkers. These findings contribute to the rationale that women with a previous pregnancy complicated by placenta-related complications, might show altered placentation in subsequent pregnancies compared with women without such previous complications.
It has been shown that placenta-related pregnancy complications such as PE have heterogeneous etiologies with similar clinical presentations. Pathophysiological mechanisms vary between early-onset and late-onset disease. Early-onset PE is more often associated with abnormal placentation. Therefore it can be assumed that biomarkers for placental function are abnormal in these cases and that histological evidence of abnormal placentation could be present. On the other hand, late-onset PE has been associated with maternal metabolic and cardiovascular risk factors such as obesity and diabetes mellitus rather than with abnormal placentation. These risk factors generate a higher maternal susceptibility to vasoactive factors by causing inflammatory responses (2) . Parameters of abnormal placentation in late-onset placenta-related pregnancy complications may therefore not always be present. None of the studies included in this review made a distinction between early-onset PE and/or IUGR vs. late-onset PE and/or IUGR. It is therefore possible that associations with abnormal placentation in subsequent pregnancies may have been weaker or not identified at all in the included studies.
Another problem is that methods to assess reliably the placental development and function in general are scarce and development of such methods is challenging. Markers of placentation, such as Doppler profiles or blood biomarkers, only reflect maternal (vascular) conditions that affect placental development or are biological products of placental function. However, these markers do not actually enable direct in vivo assessment of the placenta and, due to the complex nature of placental development, it is unlikely that such biomarkers in itself provide an accurate reflection of placentation. Therefore, the combined use of biomarkers in prediction models for placenta-related complications is often proposed (27) (28) (29) (30) (31) . As corroborated by our results, placental development and function is probably more accurately reflected by histological parameters. However, a natural limitation to the use of histological parameters is that these cannot be studied in an ongoing pregnancy. Other methods to study non-invasively the early placentation in utero is by using three-dimensional (3D) power Doppler ultrasound. This technique enables visualization of the placental vasculature in more detail and has been shown to be associated with placenta-related pregnancy complications. A recent systematic review and meta-analysis showed that in particular the vascularization index and the vascularization flow index most accurately predicted early-onset PE (32) .
In conclusion, we identified associations between women with a history of placenta-related pregnancy complications and abnormal placental development and function in subsequent pregnancies, implicating underlying endothelial dysfunction. The associations were mainly reflected in placental histological findings at term. We stress that these associations are understudied and that underlying pathophysiological mechanisms are therefore unclear. However, it is clear that cardiovascular risk factors in women predispose to placenta-related complications, especially in early-onset PE and IUGR, and make recurrence of placenta-related complications in subsequent pregnancies more likely. Considering the effects of placenta-related pregnancy complications on maternal and neonatal health, we recommend that future research should focus on abnormal placentation after placentarelated complications and its association with biomarkers of placental development function. This should preferably be performed in larger prospective cohort studies including on preconceptional and/or interconceptional women. In these women, the presence of predisposing cardiovascular risk factors and endothelial dysfunction can be assessed and associated with subsequent placental development and function. More biomarkers and ultrasound markers should be studied to expand our insights into the pathophysiology of placental development and function. Finally, further studies are needed to assess the role of ultrasound, maternal serum biomarkers and placental histology in the index pregnancy in the prediction of (recurrence of) placentarelated pregnancy complications in subsequent pregnancies. Together, this could ultimately enable a strategy for prediction of the recurrence of placenta-related complications as early in pregnancy as possible.
